Formulation Development
Evonik Launches Advanced Combination Polymer; Sets New Benchmark for Enteric Coatings
Evonik, a global leader for functional excipients used in oral solid dosage forms, recently announced the launch of an advanced combination polymer for enteric coatings.
ARTIFICIAL INTELLIGENCE - 3Ds Powering AI in Drug Discovery – Domain Expertise, Deep Learning & Data
Liran Belenzon and Simon Smith counter skepticism about AI with concrete data on recent exponential progress, provide examples of companies applying these advances to drug discovery, and show how those combining domain expertise, deep learning, and proprietary data are excelling.
BUCCAL FILMS - Better Drug Release & Patient Experiences With Buccal Films
Robert Davidson and Jessica Rousset explain how buccal administration further represents a better alternative to injections or tablets for those patients who have difficulty swallowing.
EXECUTIVE INTERVIEW - JRF Global: Innovating Drug Discovery & Development Solutions for Your Leads
Sameer Navalgund, Global Director at JRF Global, shares his perspective about the on-going trends, current status, and some of the upcoming biggest challenges in the contract services industry.
MARKET BRIEF - Alzheimer’s Disease Market Report (2016-2026)
Akiko Fukui, MSc, indicates that amid several failures, the AD pipeline is large and consists of many novel mechanisms, which makes it an exciting market undergoing rapid changes despite its high risk.
THERAPEUTIC FOCUS - Applying the HIV Treatment Model to Hepatitis B – Can a Cocktail Provide a Cure?
James Sapirstein, RPh, says in the ongoing search for a cure to hepatitis B, experts now believe that combining different drugs into a single regimen can work together against HBV and will be the most likely way to achieve a cure.
EXECUTIVE INTERVIEW - BriaCell Therapeutics: Recognizing the Power of Targeted Immunotherapies
Dr. William “Bill” Williams, MD, President and CEO of BriaCell Therapeutics, discusses the value of targeted immunotherapies in the biopharmaceutical industry.
AAPS BRIEF - Personalized Medicines for Oral Drug Delivery Devices: Definitely NOT Your Father’s Tablets
Christopher McCurdy, PhD, explains how the incorporation of 3D printing technology, made a reality with the approval of the first 3D-printed pharmaceutical by Aprecia, increased the research and interest around 3D printed formulations, and now, highly sophisticated tablets are being developed.
Ajinomoto Althea & OmniChem Combine to Form Ajinomoto Bio-Pharma Services
Ajinomoto Althea and OmniChem, global leaders in large and small molecule contract manufacturing services, recently announced they are integrating their businesses and operations as a…
Cerecor to Acquire Ichorion Therapeutics; Transaction Worth $26.6 Million
Cerecor Inc. recently announced it has agreed to acquire Ichorion Therapeutics, Inc. Ichorion is a privately-held biopharmaceutical company focused on developing treatments and increasing awareness…
Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials
Ovid Therapeutics Inc. recently announced initiations of the Phase 2 ELEKTRA and ARCADE trials for OV935/TAK-935 in pediatric patients with rare epilepsies. The company reports…
VisionGate Presents Breakthrough Research on Cell-CT Platform
VisionGate recently presented two peer-reviewed poster presentations at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC)…
Cobra Biologics, GE Healthcare & Centre for Process Innovation Collaborate to Advance Gene Therapy
Cobra Biologics recently announced a collaboration with the Centre for Process Innovation (CPI), a UK-based technology innovation centre and GE Healthcare Life Sciences. The three-way…
Immutep Enters Into Clinical Trial Collaboration & Supply Agreement With Merck & Pfizer
Immutep Limited recently announced it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to evaluate…
Akcea & Ionis Report Positive Data From Phase 2 Study Akcea & Ionis Report Positive Data From Phase 2 Study
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. recently announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).
Brammer Bio Announces Progress on $200-Million Program to Advance Gene Therapies
Brammer Bio recently announced that a 3-year, $200-million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.
Catalent Selected to Provide Oral Delivery Systems for GB Sciences’ Proprietary Parkinson’s Disease Therapies
GB Sciences, Inc. and Catalent Pharma Solutions recently announced that GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences’ proprietary active pharmaceutical ingredients (APIs) for its Parkinson’s disease therapies.
Inovio Develops Novel H3N2 Influenza DNA Vaccine; Generates Cross-Reactive Responses & Provides Complete Protection Against Lethal Preclinical Challenges
Inovio Pharmaceuticals, Inc. recently announced its SynCon vaccine approach using a collection of DNA antigens generated broadly protective antibody responses against the most deadly strains…
ContraVir Pharmaceuticals Announces Completion of Phase 1 With CRV431
ContraVir Pharmaceuticals, Inc. recently announced that the primary endpoints of safety and tolerability were met in a single ascending dose (SAD) study of CRV431 conducted…
Neurimmune Achieves Milestone in Collaboration With Ono Pharmaceutical
Neurimmune recently announced the achievement of a key preclinical milestone in the ongoing collaboration with Ono Pharmaceutical Co., Ltd. In November 2017, the parties entered…
